EA201101308A1 - Применение ралфинамида для лечения биполярного расстройства - Google Patents

Применение ралфинамида для лечения биполярного расстройства

Info

Publication number
EA201101308A1
EA201101308A1 EA201101308A EA201101308A EA201101308A1 EA 201101308 A1 EA201101308 A1 EA 201101308A1 EA 201101308 A EA201101308 A EA 201101308A EA 201101308 A EA201101308 A EA 201101308A EA 201101308 A1 EA201101308 A1 EA 201101308A1
Authority
EA
Eurasian Patent Office
Prior art keywords
bipolar disorder
treatment
ralfinamide
application
pharmaceutically acceptable
Prior art date
Application number
EA201101308A
Other languages
English (en)
Other versions
EA025326B1 (ru
Inventor
Елена Барбанти
Карла Каччья
Патричия Сальвати
Франческо Веларди
Тициано Руффилли
Луиджи Богонья
Original Assignee
Ньюрон Фармасьютикалс С.П.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37101658&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201101308(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ньюрон Фармасьютикалс С.П.А. filed Critical Ньюрон Фармасьютикалс С.П.А.
Publication of EA201101308A1 publication Critical patent/EA201101308A1/ru
Publication of EA025326B1 publication Critical patent/EA025326B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/08—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/12—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
    • C07C233/13—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/10—Preparation of carboxylic acid amides from compounds not provided for in groups C07C231/02 - C07C231/08
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/16—Preparation of optical isomers
    • C07C231/18—Preparation of optical isomers by stereospecific synthesis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение относится к применению ралфинамида высокой степени чистоты или его соли фармацевтически приемлемой кислоты, где содержание соответствующей примеси (S)-2-[3-(2-фторбензил)-4-(2-фторбензилокси)бензиламино]пропанамида (IIb) или его соли фармацевтически приемлемой кислоты ниже 0,03 мас.%, для производства лекарственного препарата для лечения биполярного расстройства. Изобретение также относится к способу лечения биполярного расстройства с использованием упомянутого выше соединения.
EA201101308A 2006-06-19 2007-06-08 Применение сафинамида и ралфинамида высокой степени чистоты для лечения заболеваний и болезненных состояний в условиях, не препятствующих активности цитохромов системы cyp450 и не проявляющих блокирующих свойств в отношении herg канала EA025326B1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06012565 2006-06-19

Publications (2)

Publication Number Publication Date
EA201101308A1 true EA201101308A1 (ru) 2012-02-28
EA025326B1 EA025326B1 (ru) 2016-12-30

Family

ID=37101658

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201101308A EA025326B1 (ru) 2006-06-19 2007-06-08 Применение сафинамида и ралфинамида высокой степени чистоты для лечения заболеваний и болезненных состояний в условиях, не препятствующих активности цитохромов системы cyp450 и не проявляющих блокирующих свойств в отношении herg канала
EA200970028A EA017123B1 (ru) 2006-06-19 2007-06-08 Способ получения 2-[4-(3- и 2-фторбензилокси)бензиламино]пропанамидов

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA200970028A EA017123B1 (ru) 2006-06-19 2007-06-08 Способ получения 2-[4-(3- и 2-фторбензилокси)бензиламино]пропанамидов

Country Status (27)

Country Link
US (2) US8076515B2 (ru)
EP (2) EP2474521B1 (ru)
JP (2) JP5240476B2 (ru)
KR (2) KR101491541B1 (ru)
CN (2) CN103284984B (ru)
AR (1) AR061510A1 (ru)
AU (1) AU2007263328C1 (ru)
BR (1) BRPI0712936B8 (ru)
CA (1) CA2653012C (ru)
CY (2) CY1115951T1 (ru)
DK (2) DK2029524T3 (ru)
EA (2) EA025326B1 (ru)
ES (2) ES2602069T3 (ru)
HK (1) HK1130245A1 (ru)
HR (2) HRP20150136T1 (ru)
HU (1) HUE030233T2 (ru)
IL (1) IL195294A (ru)
LT (1) LT2474521T (ru)
MX (2) MX2008015704A (ru)
NO (2) NO342018B1 (ru)
NZ (2) NZ595737A (ru)
PL (2) PL2029524T3 (ru)
PT (2) PT2029524E (ru)
RS (2) RS53824B1 (ru)
SI (2) SI2029524T1 (ru)
TW (2) TWI393700B (ru)
WO (1) WO2007147491A1 (ru)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1658062B1 (en) * 2003-08-25 2010-02-17 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful as anti-inflammatory agents
RS53824B1 (en) * 2006-06-19 2015-06-30 Newron Pharmaceuticals S.P.A. PROCESS FOR OBTAINING 2- [4- (3-AND 2-FLUOROBENZYLOXY) BENZYLAMINO] PROPANAMIDE
DK2229351T3 (en) * 2007-12-11 2018-01-22 Newron Pharm Spa PROCEDURE FOR THE PREPARATION OF 2- [4- (3- OR 2-FLUORBENZYLOXY) BENZYLAMINO] PROPANAMIDS WITH HIGH PURITY
EP2314569A1 (en) * 2009-10-22 2011-04-27 Merck Patent GmbH Novel polymorphic forms of (S)-2-[4-(3-Fluoro-benzyloxy)-benzylamino]-propionamide mesylate salt and processes of manufacturing thereof
LT2563355T (lt) * 2010-04-27 2016-09-26 Newron Pharmaceuticals S.P.A. Ralfinamido metansulfonato druskų arba jų r-enentiomerų gavimo būdas
RU2015122615A (ru) 2012-12-03 2017-01-10 Ф. Хоффманн-Ля Рош Аг Замещенные соединения амида изоксазола в качестве ингибиторов стеароил-коа-десатуразы 1 (скд1)
WO2014178083A1 (en) 2013-05-03 2014-11-06 Council Of Scientific & Industrial Research An improved synthesis of anti-parkinson agent
CN104292128A (zh) * 2014-07-01 2015-01-21 南京正科制药有限公司 一种沙芬酰胺晶型a
JP6466109B2 (ja) * 2014-09-09 2019-02-06 東ソー・ファインケム株式会社 ２−ベンジルオキシ−５−（トリフルオロメチル）ピリミジン誘導体及びその製造方法
CN105017060B (zh) * 2015-07-03 2017-06-16 南京正大天晴制药有限公司 一种沙芬酰胺新晶型及其制备方法
CN113072436A (zh) * 2015-07-24 2021-07-06 上海医药集团股份有限公司 一种苄基芳基醚的制备方法
CN105061245A (zh) * 2015-08-25 2015-11-18 成都维恒医药科技有限公司 一种高纯度沙芬酰胺的制备方法
CN106220525A (zh) * 2016-07-31 2016-12-14 合肥远志医药科技开发有限公司 一种工业化沙芬酰胺甲磺酸盐的制备方法
CN106336363B (zh) * 2016-08-22 2018-10-30 上海医药集团股份有限公司 一种沙芬酰胺甲磺酸盐晶型c及其制备方法
CN106565521B (zh) * 2016-08-24 2019-03-08 浙江美诺华药物化学有限公司 (s)-2-[3-(3-氟苄基)-4-(3-氟苄氧基)苄氨基]丙酰胺及其盐的制备方法
CN106596828B (zh) * 2016-12-15 2018-09-25 扬子江药业集团有限公司 一种甲磺酸沙芬酰胺有关物质的检测方法
CN107271600B (zh) * 2017-07-28 2019-01-25 成都百裕制药股份有限公司 一种4-(3-氟苄氧基)苯甲醛中异构体杂质含量的检测方法
CN107857713A (zh) * 2017-11-23 2018-03-30 江苏恒盛药业有限公司 一种沙芬酰胺氢溴酸盐及其一种晶型
CN107759487A (zh) * 2017-11-23 2018-03-06 江苏恒盛药业有限公司 一种沙芬酰胺盐酸盐及其一种晶型以及制备方法
WO2019167085A1 (en) * 2018-03-01 2019-09-06 Msn Laboratories Private Limited, R&D Center Process for the preparation of (s)-2-[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]amino propanamide methanesulfonate
US11111208B2 (en) 2019-06-17 2021-09-07 RK Pharma Solutions LLC Process for the preparation of safinamide mesylate intermediate
ES2977486T3 (es) * 2019-08-06 2024-08-26 Medichem Sa Proceso para preparar safinamida
CN111122736B (zh) * 2019-12-30 2021-03-12 北京鑫开元医药科技有限公司海南分公司 一种用于检测布瓦西坦中间体中对映异构体的方法
CN113214097B (zh) * 2020-01-21 2022-08-30 厦门大学 治疗阿尔茨海默病的化合物
CN112028754A (zh) * 2020-06-17 2020-12-04 浙江美诺华药物化学有限公司 一种甲磺酸沙芬酰胺中间体的制备方法
CN114088830B (zh) * 2021-11-10 2022-09-23 石家庄四药有限公司 一种4-(3-氟苄氧基)苯甲醛中异构体的检测方法
CN116008439B (zh) * 2023-02-20 2023-10-27 山东绿叶制药有限公司 一种检测2,6-二氧杂螺[4,5]癸烷类化合物或其盐中杂质的方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94466A (en) 1989-05-25 1995-01-24 Erba Carlo Spa Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation
GB9727523D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
EP0974351A3 (en) * 1998-04-24 2000-12-13 Jouveinal Medicament for preventing and treating gastrointestinal damage
AU2001249610B2 (en) 2000-03-31 2005-03-24 Euro-Celtique S.A. Aminopyridines and their use as anticonvulsants and sodium channel blockers
AU2002333374B2 (en) 2001-09-03 2007-03-22 Newron Pharmaceuticals S.P.A. Pharmaceutical composition comprising gabapentin or an analogue thereof and an (alpha)- aminoamide and its analgesic use
EP1438956A1 (en) * 2003-01-16 2004-07-21 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful as antimigraine agents
EP1589959A2 (en) * 2003-01-30 2005-11-02 Dynogen Pharmaceuticals Inc. Methods of treating lower urinary tract disorders using sodium channel modulators
JP2006515326A (ja) * 2003-01-30 2006-05-25 ダイノジェン ファーマシューティカルズ， インコーポレイテッド 胃腸管障害を処置するためのナトリウムチャネルモジュレーターの使用
AR044007A1 (es) 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
TW200507850A (en) * 2003-07-25 2005-03-01 Kyowa Hakko Kogyo Kk Pharmaceutical composition
EP1658062B1 (en) * 2003-08-25 2010-02-17 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful as anti-inflammatory agents
EP1524267A1 (en) 2003-10-15 2005-04-20 Newron Pharmaceuticals S.p.A. Substituted benzylaminoalkylene heterocycles
EP1557166A1 (en) * 2004-01-21 2005-07-27 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders
EP1588704A1 (en) 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
SI1809271T1 (sl) * 2004-09-10 2010-10-29 Newron Pharm Spa Uporaba (R)-(halobenziloksi) benzilamino propanamidov kot selektivnih modulatorjev natrijevih in/ali kalcijevih kanalov
EP1870097A1 (en) * 2006-06-15 2007-12-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
RS53824B1 (en) * 2006-06-19 2015-06-30 Newron Pharmaceuticals S.P.A. PROCESS FOR OBTAINING 2- [4- (3-AND 2-FLUOROBENZYLOXY) BENZYLAMINO] PROPANAMIDE
DK2229351T3 (en) * 2007-12-11 2018-01-22 Newron Pharm Spa PROCEDURE FOR THE PREPARATION OF 2- [4- (3- OR 2-FLUORBENZYLOXY) BENZYLAMINO] PROPANAMIDS WITH HIGH PURITY
JP5736175B2 (ja) * 2007-12-19 2015-06-17 ニユーロン・フアーマシユーテイカルズ・エツセ・ピー・アー 精神障害の治療に有用なα−アミノアミド誘導体

Also Published As

Publication number Publication date
CN103284984B (zh) 2016-08-03
LT2474521T (lt) 2016-11-25
NO20171916A1 (no) 2009-01-16
US20090156678A1 (en) 2009-06-18
NO342644B1 (no) 2018-06-25
US20120157712A1 (en) 2012-06-21
SI2474521T1 (sl) 2016-12-30
TWI412512B (zh) 2013-10-21
US8278485B2 (en) 2012-10-02
RS55464B1 (sr) 2017-04-28
NZ572798A (en) 2011-11-25
CN103284984A (zh) 2013-09-11
PL2474521T3 (pl) 2017-01-31
AU2007263328B2 (en) 2012-03-22
KR20140027563A (ko) 2014-03-06
TWI393700B (zh) 2013-04-21
MX2008015704A (es) 2009-01-09
PT2029524E (pt) 2015-03-09
NO342018B1 (no) 2018-03-12
AU2007263328C1 (en) 2012-09-06
HUE030233T2 (en) 2017-04-28
MX342698B (es) 2016-10-10
DK2474521T3 (en) 2016-10-31
SI2029524T1 (sl) 2015-03-31
PT2474521T (pt) 2016-11-10
JP5795342B2 (ja) 2015-10-14
EP2029524B1 (en) 2014-11-26
BRPI0712936B8 (pt) 2021-05-25
AU2007263328A1 (en) 2007-12-27
BRPI0712936B1 (pt) 2021-02-23
JP2013139446A (ja) 2013-07-18
JP5240476B2 (ja) 2013-07-17
IL195294A (en) 2015-03-31
ES2527437T3 (es) 2015-01-26
JP2009541232A (ja) 2009-11-26
TW201313662A (zh) 2013-04-01
TW200815322A (en) 2008-04-01
KR101410291B1 (ko) 2014-06-20
CN101472880A (zh) 2009-07-01
US8076515B2 (en) 2011-12-13
AR061510A1 (es) 2008-09-03
CN101472880B (zh) 2013-04-24
EP2474521B1 (en) 2016-08-10
CA2653012C (en) 2014-08-05
EA025326B1 (ru) 2016-12-30
AU2007263328A2 (en) 2009-02-19
CA2653012A1 (en) 2007-12-27
HRP20150136T1 (en) 2015-03-13
EA200970028A1 (ru) 2009-06-30
PL2029524T3 (pl) 2015-04-30
WO2007147491A1 (en) 2007-12-27
EA017123B1 (ru) 2012-10-30
KR20090021392A (ko) 2009-03-03
KR101491541B1 (ko) 2015-02-09
HK1130245A1 (en) 2009-12-24
CY1115951T1 (el) 2017-01-25
ES2602069T3 (es) 2017-02-17
NZ595737A (en) 2013-04-26
HRP20161456T1 (hr) 2016-12-16
BRPI0712936A2 (pt) 2012-12-18
IL195294A0 (en) 2009-08-03
DK2029524T3 (da) 2015-02-23
EP2029524A1 (en) 2009-03-04
EP2474521A1 (en) 2012-07-11
NO20090231L (no) 2009-01-16
CY1118113T1 (el) 2017-06-28
RS53824B1 (en) 2015-06-30

Similar Documents

Publication Publication Date Title
EA201101308A1 (ru) Применение ралфинамида для лечения биполярного расстройства
IS2533B (is) (S)-2-N-própýlamínó-5-hýdroxýetralín sem D3-gerandefni
GEP20156366B (en) Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
GEP20125566B (en) Aryl-and heteroaryl-substituded tetrahydro-benzazepines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
MX2007006082A (es) Tetrahidroisoquinolinas aril- y heteroaril-sustituidas, y uso de las mismas para bloquear la recaptacion de norepinefrina, dopamina y serotonina.
ATE450514T1 (de) Piperazinylalkylpyrazol-derivate zur verwendung als selektive calciumkanalblocker des t-typs und verfahren zu ihrer herstellung
TW201000473A (en) Benzene or thiophene derivative and use thereof as VAP-1 inhibitor
AU2018236805B2 (en) Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
TW200744586A (en) Therapeutic compounds
EA201270560A1 (ru) Спиропиперидиновые соединения и их фармацевтическое применение для лечения диабета
EA201391486A1 (ru) Способы и композиции для лечения болезни паркинсона
WO2009066041A3 (fr) Derives de 1,2,4,5-tetrahydro-3h-benzazepines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
TW200806299A (en) Treatment of pain
WO2012018534A3 (en) Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
TW200639159A (en) Treatment of pain
UA114405C2 (uk) Феніл-3-азабіцикло[3.1.0]гекс-3-илметанони та їх застосування як лікарського засобу
EA201070442A1 (ru) НОВЫЕ ИНГИБИТОРЫ sEH И ИХ ПРИМЕНЕНИЕ
MX2011009709A (es) Compuestos para el tratamiento de la inflamacion y del dolor.
MX2021010046A (es) Nueva composicion terapeutica que contiene ingrediente activo de apomorfinas.
EP1627635A3 (en) Benzothiazolium compounds for use in methods of inhibiting NO production and TNF alpha and treating coronaviral infection
UA107562C2 (uk) Спосіб лікування псоріазу
MY149058A (en) N-(2-aminophenyl)-4-[n-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (ms-275) polymorph b
EA201391026A1 (ru) Кристаллическое производное оксазина и его применение в качестве ингибитора bace
MX2010010595A (es) Proceso para la preparacion de sulfamatos de heteroarilo benzofusionado y la forma cristalina de n-(((2s)-6-cloro-2,3-dihid ro-1,4-benzodioxin-2il)metil-sulfamida.